|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||604.00 - 652.80|
|52 Week Range||295.03 - 652.80|
|PE Ratio (TTM)||85.09|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biocon Ltd. said it signed a deal to develop copycat versions of biologic drugs with a unit of Novartis AG, its latest move to become a global player in the next generation of generic medicines after a ...
Measuring Biocon Limited’s (NSEI:BIOCON) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, whichRead More...
Biocon Limited’s (NSEI:BIOCON) most recent return on equity was a substandard 10.42% relative to its industry performance of 16.12% over the past year. Though BIOCON’s recent performance is underwhelming, itRead More...
Dec 26 (Reuters) - Kelington Group Bhd: * UPDATES ON APPLICATION FOR ENFORCEMENT OF ADJUDICATION DECISION BY KELINGTON TECHNOLOGIES SDN BHD AGAINST BIOCON SDN BHD * HIGH COURT ALLOWED UNIT’S APPLICATION ...
Biocon Ltd. has received U.S. Food and Drug Administration clearance for the sterile products unit of its Bengaluru facility, a sign of progress in its bid to bring the plant up to regulatory standards ...
(Reuters) - India's Biocon Ltd posted a 53 percent fall in quarterly profit on Thursday, missing estimates, as higher costs at its Malaysia plant and pricing pressures in its active pharmaceutical ingredients ...
Oct 26 (Reuters) - Biocon Ltd * Sept quarter consol profit 688 million rupees versus 1.47 billion rupees last year * Consensus forecast for Sept quarter consol profit was 1.14 billion rupees * Sept quarter ...
Biosimilar drugmakers are eager to launch competitors to Amgen's drugs, but one big competitor is going to have to wait a while longer.
Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients. Shares of Coherus tumbled 30 percent to $14.47 in morning trading, while Amgen's shares were up slightly at $164.19.
India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.
Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.